Study guide
Advanced & Refractory ICP Interventions
ABPN Neurocritical Care Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU
Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU
2 Chapter 2: Cerebral Physiology & Intracranial Dynamics
Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes
3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management
Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions
4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management
Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy
5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management
Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury
6 Chapter 6: Neuropharmacology, Analgesia & Sedation
ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU
7 Bleeding, Thrombosis & Hematologic Emergencies
Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity
8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine
Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention
9 Systemic Trauma & Environmental Injury
Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging
10 Cardiac Emergencies & Mechanical Support
IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies
11 Kidney Injury, Acid–Base & Renal Replacement
Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement
12 Systemic Infection & Endocrine Emergencies
Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies
13 Gastrointestinal & Hepatic Emergencies
Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects
14 Chapter 9: Neuroimaging in the Neuro-ICU
Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness
15 Chapter 10: Electrophysiology & Neuromonitoring
Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler
16 Angiography, Electrodiagnosis & CSF Analysis
Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage
17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria
Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria
18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies
Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction
19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage
Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH
20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia
Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations
21 Venous, Spinal & Traumatic Vascular Disease
Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury
22 Chapter 15: Traumatic Brain & Spinal Cord Injury
Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes
23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies
Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure
24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis
Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies
25 Neuroinflammation & Neurooncology
Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies
26 Pregnancy, Transplantation & Pediatric Care
Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care
27 Chapter 18: Neurosurgical & Perioperative Emergencies
Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies
28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU
Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor
Advanced & Refractory ICP Interventions
Key Takeaways Explain This Topic AI
Tier 2 interventions encompass neuromuscular blockade (eliminating ventilator dyssynchrony and thoracoabdominal pressure spikes) and moderate hypocapnia (PaCO2 30-35 mmHg) strictly guarded by multimodal neuromonitoring (PbtO2 >= 20 mmHg).
High-dose barbiturates may control refractory ICP, but require EEG, blood-pressure, and toxicity monitoring; titrate to the clinical protocol rather than an arbitrary bursts-per-page target.
The Eurotherm3235 trial established that routine early therapeutic hypothermia (32-35 °C) in TBI increases 6-month unfavorable functional outcomes and mortality, rendering early hypothermia contraindicated.
The landmark RESCUEicp trial proved that decompressive craniectomy for sustained refractory ICP > 25 mmHg reduces 6-month mortality by 22% compared to medical management, but increases survival with vegetative state and severe disability.
Do not use corticosteroids to treat TBI edema or improve TBI outcome; CRASH found increased mortality with high-dose methylprednisolone.
Last updated: October 2026
Advanced & Refractory Intracranial Pressure Interventions
Refractory intracranial hypertension occurs when intracranial pressure remains sustained above 22 to 25 mmHg despite maximal Tier 0 baseline support and Tier 1 interventions (CSF drainage, hyperosmolar boluses, and moderate sedation). Refractory elevations represent a pre-terminal physiological state that rapidly precipitates irreversible brainstem herniation and secondary cerebral infarction.
Managing refractory ICP requires escalating to Tier 2 and Tier 3 therapies. Because these advanced interventions carry substantial procedural, hemodynamic, and systemic morbidity, their implementation is governed by rigorous pathophysiologic endpoints and landmark clinical trial evidence.
- Tier 2 Interventions: Neuromuscular Blockade and Monitored Hypocapnia
- 1. Neuromuscular Blockade (NMBAs)
When patient-ventilator dyssynchrony, vigorous coughing, shivering, or spontaneous decerebrate/decorticate posturing drives intracranial pressure spikes, complete neuromuscular blockade is deployed. Non-depolarizing agents such as cisatracurium (preferred due to organ-independent Hofmann elimination) or vecuronium are administered via intermittent boluses or continuous infusion.
Mechanism : Eliminates muscular contraction, immediately reducing intrathoracic and intra-abdominal pressures. This relieves impediment to superior vena cava and internal jugular venous drainage, reducing cerebral venous blood volume and lowering ICP.
Mandatory Precautions :
Deep sedation and analgesia must be confirmed before paralysis to eliminate the horror of awake awareness.
Train-of-Four (TOF) peripheral nerve monitoring (targeting 1–2 twitches out of 4) is required to prevent drug accumulation and persistent post-paralytic paresis.
Continuous EEG (cEEG) is essential because neuromuscular blockade masks all outward motor manifestations of clinical seizures and non-convulsive status epilepticus.
Prolonged use increases the risk of critical illness polyneuropathy and myopathy (CIPNM), deep vein thrombosis, and decubitus ulceration.
2. Controlled Moderate Hypocapnia with Multimodal Neuromonitoring
Controlled hyperventilation to a target P a C O 2 PaCO_2 P a C O 2 of 30 to 35 mmHg can be maintained in Tier 2, but ONLY when accompanied by continuous advanced neuromonitoring .
Hypocapnia induces extracellular alkalosis around cerebral resistance arterioles, triggering smooth muscle constriction, reduced cerebral blood volume (CBV), and rapid ICP reduction. However, excessive vasoconstriction reduces cerebral blood flow below the ischemic threshold ( C B F < 18 – 20 mL / 100 g / min CBF < 18\text{--}20\text{ mL}/100\text{ g}/\text{min} CBF < 18 – 20 mL /100 g / min ).
Mandatory Neuromonitoring Guards :
Brain Tissue Oxygen Tension ( P b t O 2 PbtO_2 P b t O 2 ) : Must be maintained ≥ 20 mmHg \ge 20\text{ mmHg} ≥ 20 mmHg . If hyperventilation drops P b t O 2 < 20 mmHg PbtO_2 < 20\text{ mmHg} P b t O 2 < 20 mmHg , hypocapnia must be immediately reversed.
Jugular Venous Bulb Oxygen Saturation ( S j v O 2 SjvO_2 S j v O 2 ) : Must remain between 55 % 55\% 55% and 75 % 75\% 75% . An S j v O 2 < 50 – 55 % SjvO_2 < 50\text{--}55\% S j v O 2 < 50 – 55% indicates cerebral hyper-extraction and critical hypoperfusion.
Note
Avoid routine prophylactic hypocapnia. If hyperventilation is used for raised ICP, monitor oxygen delivery when feasible and minimize exposure. Do not delay a brief emergency herniation bridge while awaiting an invasive probe; deploy definitive treatment urgently.
Tier 3 Interventions: High-Dose Barbiturate Coma
When intracranial hypertension resists Tier 2 therapies, high-dose barbiturates represent the most potent medical intervention to halt metabolic activity.
Mechanism of Action
Barbiturates (primarily pentobarbital or thiopental) bind allosterically to G A B A A GABA_A G A B A A receptors, prolonging chloride channel opening and producing profound neuronal hyperpolarization. This completely suppresses electrophysiologic synaptic transmission, decreasing the cerebral metabolic rate of oxygen ( C M R O 2 CMRO_2 CMR O 2 ) by up to 50% . Through neurovascular coupling, this metabolic shutdown induces profound precapillary vasoconstriction, reducing cerebral blood volume and intracranial pressure.
Titration endpoint: Titrate to ICP control with continuous EEG and systemic monitoring, avoiding unnecessary drug exposure. Burst suppression may be used under a defined protocol, but a fixed number of bursts per screen or suppression ratio is not a universal validated optimum; screen duration and the clinical indication matter.
Important
Titrating barbiturates beyond burst suppression to achieve complete electrocerebral silence (flatline EEG) provides NO additional reduction in C M R O 2 CMRO_2 CMR O 2 or ICP because basal metabolic needs for cellular membrane viability cannot be abolished. Over-titration exponentially escalates fatal cardiovascular collapse.
Life-Threatening Adverse Effects and Management
Severe Hypotension & Myocardial Depression : Barbiturates directly depress myocardial contractility and blunt sympathetic vascular tone, causing profound systemic vasodilation. Aggressive continuous vasopressor support (norepinephrine, epinephrine) and appropriate pressure and perfusion monitoring are required, with advanced cardiac-output monitoring selected when indicated to preserve CPP ≥ 60 mmHg \ge 60\text{ mmHg} ≥ 60 mmHg .
Loss of Clinical Neurologic Examination : High-dose barbiturates can markedly suppress cortical activity and brainstem responses (corneal, oculocephalic, gag, and cough reflexes). Pupillary light reflexes typically persist but may become sluggish; pupillary dilation and unresponsiveness can mimic herniation.
Other Toxicities : Paralytic ileus, hepatic dysfunction, severe hypothermia, and extreme immunosuppression leading to life-threatening nosocomial pneumonia and catheter-related bloodstream infections.
Therapeutic Hypothermia: The Eurotherm3235 Evidence
Induced moderate hypothermia ( 32 to 34 ∘ C 32\text{ to }34^\circ\text{C} 32 to 3 4 ∘ C ) lowers C M R O 2 CMRO_2 CMR O 2 by 7 to 10 % 7\text{ to }10\% 7 to 10% per 1 ∘ C 1^\circ\text{C} 1 ∘ C drop, decreases free radical production, stabilizes the blood-brain barrier, and suppresses inflammatory cascades.
Guidance: BTF does not recommend early short-term prophylactic hypothermia to improve outcomes in diffuse severe TBI. Eurotherm3235 tested ICP-directed hypothermia and found worse outcomes. Distinguish those populations and use the guideline’s own evidence levels; do not translate them into an invented AHA Class III label.
Warning
Routine therapeutic hypothermia does NOT improve outcomes in traumatic brain injury and was proven harmful in the Eurotherm3235 trial. Strict normothermia ( 36.0 – 37.5 ∘ C 36.0\text{--}37.5^\circ\text{C} 36.0 – 37. 5 ∘ C ) is the standard of care.
Surgical Decompression: Decompressive Craniectomy & Landmark Trials
Surgical decompression eliminates the rigid boundaries of the skull, converting a closed, non-compliant intracranial cavity into an open system to normalize compliance.
Surgical Techniques
Unilateral Frontotemporoparietal Decompressive Hemicraniectomy : Removal of a large bone flap ( diameter ≥ 12 to 15 cm \ge 12\text{ to }15\text{ cm} ≥ 12 to 15 cm ) extending to the floor of the middle cranial fossa, paired with expansive duraplasty. Indicated for unilateral mass lesions, acute subdural hematomas, and malignant hemispheric ischemic stroke.
Pitfall : An inadequately sized decompression can be harmful; operative size depends on anatomy and the planned procedure; swollen brain herniates through a small window, causing venous kinking, contusional laceration, and hemorrhagic necrosis along the bone edge.
Bifrontal Decompressive Craniectomy : Coronal incision with bilateral frontal bone removal extending to the orbital rims; indicated for diffuse, symmetric traumatic brain swelling.
The Landmark Trials: DECRA vs RESCUEicp
Trial Population Intervention Primary Outcome Long-Term Clinical Conclusion
DECRA (NEJM 2011) Severe TBI with early diffuse brain swelling and moderate ICP ( > 20 mmHg > 20\text{ mmHg} > 20 mmHg for > 15 min > 15\text{ min} > 15 min within 1 h 1\text{ h} 1 h ) Early bifrontal craniectomy vs medical care Craniectomy decreased ICP and ICU length of stay, but significantly increased unfavorable functional outcomes (GOS-E OR 1.84, p = 0.03 p = 0.03 p = 0.03 ) Ultra-early bifrontal craniectomy for mild/moderate diffuse ICP spikes is harmful and worsens functional recovery.
RESCUEicp (NEJM 2016) Severe TBI with sustained, refractory ICP ( > 25 mmHg > 25\text{ mmHg} > 25 mmHg for 1 – 12 h 1\text{--}12\text{ h} 1 – 12 h ) despite Tier 1 & 2 therapies Decompressive craniectomy (hemicraniectomy or bifrontal) vs medical care Surgery resulted in a 22-percentage-point absolute reduction in 6-month mortality ( 26.9 % 26.9\% 26.9% surgical vs 48.9 % 48.9\% 48.9% medical, p < 0.001 p < 0.001 p < 0.001 ) Craniectomy saves lives in refractory intracranial hypertension, but increases the proportion of patients surviving in vegetative and severely disabled states.
Understanding RESCUEicp Outcomes for Patient Counseling
While RESCUEicp proved craniectomy reduces mortality, the functional distribution at 6 months warrants nuanced clinical counseling:
- Mortality : 26.9 % 26.9\% 26.9% (surgical) vs 48.9 % 48.9\% 48.9% (medical)
- Vegetative State : 8.5 % 8.5\% 8.5% (surgical) vs 2.1 % 2.1\% 2.1% (medical)
Lower Severe Disability (dependent on others for daily care): 21.9 % 21.9\% 21.9% (surgical) vs 14.4 % 14.4\% 14.4% (medical)
Upper Severe Disability & Independent Recovery : Upper severe disability was more frequent after surgery (15.4% versus 8.0%); moderate disability/good recovery was similar (27.4% versus 28.3%).
Crucially, by 12 months, delayed neuroplasticity allowed a substantial proportion of surgical patients who were initially categorized as severely disabled at 6 months to transition to independent living.
The Corticosteroid Contraindication in TBI: The CRASH Trial
Glucocorticoids (such as dexamethasone) are highly effective in treating vasogenic edema surrounding brain tumors, intracranial metastases, and cerebral abscesses by restoring endothelial tight junction integrity. However, they are completely ineffective—and actively lethal—in the setting of cytotoxic and traumatic cerebral edema .
The CRASH Trial (2004)
The landmark CRASH trial (Corticosteroid Randomisation After Significant Head Injury) enrolled 10,008 adults with acute traumatic brain injury randomized within 8 hours to high-dose methylprednisolone ( 2 g 2\text{ g} 2 g loading dose followed by 0.4 g/h 0.4\text{ g/h} 0.4 g/h for 48 hours) versus placebo:
Results : High-dose corticosteroids caused a statistically significant increase in 14-day all-cause mortality ( 21.1 % 21.1\% 21.1% vs 17.9 % 17.9\% 17.9% , relative risk 1.18, p = 0.0001 p = 0.0001 p = 0.0001 ) and six-month mortality; the combined death-or-severe-disability endpoint should be distinguished from mortality alone.
Mechanism of Harm : Corticosteroids exacerbate secondary neuronal injury by inducing severe hyperglycemia, impairing cellular energetic recovery, increasing systemic immunosuppression and infection rates, and accelerating post-traumatic apoptosis.
Guideline Consensus : Corticosteroids should not be used to improve outcome or reduce ICP in severe TBI (Brain Trauma Foundation Level I recommendation against steroids for severe TBI).
Warning
High-dose corticosteroids are classified as Level I Harm in acute traumatic brain injury. The CRASH trial proved that steroids significantly increase mortality. Never administer dexamethasone or methylprednisolone for traumatic brain edema or acute ischemic stroke.